List of Excipients in Branded Drug LETAIRIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	LETAIRIS	ambrisentan	61958-0801	ALUMINUM OXIDE
Gilead Sciences Inc	LETAIRIS	ambrisentan	61958-0801	CELLULOSE, MICROCRYSTALLINE
Gilead Sciences Inc	LETAIRIS	ambrisentan	61958-0801	CROSCARMELLOSE SODIUM
Gilead Sciences Inc	LETAIRIS	ambrisentan	61958-0801	FD&C RED NO. 40

Letairis Excipient Strategy and Commercial Opportunities for Ambrisentan

Last updated: August 10, 2026

Letairis is the branded formulation of ambrisentan, an oral endothelin receptor antagonist approved for pulmonary arterial hypertension (PAH). Its commercial opportunity is now concentrated in generic manufacturing, differentiated excipient systems, supply reliability, and lifecycle products rather than conventional brand exclusivity. The core formulation is a low-complexity, immediate-release film-coated tablet, which limits formulation barriers but creates opportunities in lactose-free manufacturing, robust low-dose content uniformity, coating efficiency, and international product adaptation.

What drug and dosage forms does Letairis contain?

Letairis contains ambrisentan in 5 mg and 10 mg film-coated tablets. The product is administered orally once daily and may be taken with or without food.[1]

Attribute	Letairis
Active ingredient	Ambrisentan
Therapeutic class	Endothelin receptor antagonist
Main indication	Pulmonary arterial hypertension
Dosage form	Immediate-release film-coated tablet
Strengths	5 mg and 10 mg
Route	Oral
Reference manufacturer	Gilead Sciences
FDA product type	New drug application
Generic pathway	Abbreviated New Drug Application, or ANDA
Biosimilar exposure	None; ambrisentan is a small molecule
Food administration	With or without food
Main formulation challenge	Dose uniformity and dissolution at low tablet strengths

Ambrisentan is a small-molecule active pharmaceutical ingredient. The product does not require biologic stabilization, sterile processing, refrigeration, device assembly, or complex drug delivery technology.

What excipients are used in Letairis tablets?

The Letairis formulation uses conventional solid-dose excipients. The inactive ingredients identified in U.S. labeling include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, and FD&C Red No. 40 aluminum lake.[1]

Formulation function	Letairis excipient
Diluent and bulk-forming agent	Lactose monohydrate
Compressibility aid	Microcrystalline cellulose
Superdisintegrant	Croscarmellose sodium
Lubricant	Magnesium stearate
Film-forming polymer	Polyvinyl alcohol
Opacifier and pigment carrier	Titanium dioxide
Anti-tacking and coating aid	Talc
Plasticizer or coating modifier	Polyethylene glycol
Colorant	FD&C Red No. 40 aluminum lake

The excipient system is commercially conventional. No modified-release polymer, lipid vehicle, amorphous solid dispersion, enteric coating, or specialized solubilizer is required for the labeled tablet.

Why is lactose important in an ambrisentan generic?

Lactose is a cost-effective diluent with broad use in immediate-release tablets. It can support tablet weight, compressibility, and manufacturing economics. It also creates a clear differentiation opportunity.

A lactose-free generic could target:

• Patients with lactose intolerance or sensitivity concerns.
• Hospitals and specialty pharmacies using excipient-screened formularies.
• International markets with different labeling expectations.
• Contract manufacturing organizations seeking a common lactose-free platform.
• Products intended for future pediatric or geriatric formulation extensions.

Lactose intolerance does not generally equate to a clinically meaningful reaction to the small quantity of lactose in a tablet. Commercial positioning would therefore need to rely on formulation transparency and market access rather than broad therapeutic claims.

What is the role of microcrystalline cellulose and croscarmellose sodium?

Microcrystalline cellulose provides compactibility and tablet strength. Croscarmellose sodium promotes rapid tablet breakup after administration. The combination is appropriate for a low-dose immediate-release product in which drug distribution throughout the blend is more important than high drug loading.

Potential generic-manufacturer improvements include:

• Optimizing particle-size distribution.
• Controlling powder segregation during hopper transfer.
• Improving blend uniformity at the 5 mg strength.
• Reducing lubricant overmixing.
• Using roller compaction or optimized direct compression where justified.
• Increasing tablet robustness without delaying dissolution.

The main development risk is not excipient novelty. It is maintaining content uniformity and dissolution across commercial-scale batches.

How should a generic manufacturer design an ambrisentan excipient strategy?

A generic formulation does not need to copy every inactive ingredient in Letairis. Under the FDA ANDA framework, the product must meet applicable requirements for pharmaceutical equivalence, bioequivalence, quality, strength, dosage form, route, labeling, and manufacturing controls.[2]

A practical excipient strategy should use a risk-ranked approach.

Core strategy

The lowest-risk route is a conventional immediate-release tablet using:

• A diluent such as lactose or microcrystalline cellulose.
• A disintegrant such as croscarmellose sodium or sodium starch glycolate.
• A lubricant such as magnesium stearate or sodium stearyl fumarate.
• A conventional film-coating system.
• FDA-permitted colorants aligned with the reference product or target market.

Differentiated strategy

A manufacturer can pursue a differentiated formulation based on:

• Lactose exclusion.
• Reduced tablet mass.
• Improved mechanical strength.
• Lower coating weight.
• Color-free or dye-reduced coating.
• Alternate packaging for moisture protection.
• More efficient compression and coating throughput.
• A formulation compatible with multiple global regulatory markets.

The strongest commercial opportunity is a robust platform that supports both 5 mg and 10 mg strengths with minimal process changes. A shared formulation architecture can reduce validation cost, inventory complexity, and scale-up risk.

Excipients requiring close control

Magnesium stearate can affect wetting and dissolution if overmixed. Croscarmellose sodium can vary in swelling behavior depending on grade and processing history. Microcrystalline cellulose properties can influence tensile strength, ejection force, and disintegration. Film-coating pigments can affect appearance and process uniformity.

For a low-dose drug, excipient variability can have a larger impact on finished-product performance than the nominal quantity of each excipient suggests.

What formulation patents protect Letairis?

The principal intellectual-property position for Letairis historically centered on ambrisentan composition, pharmaceutical compositions, therapeutic use, and related patent rights rather than on a technically complex excipient platform.

Publicly available FDA and patent records should be used to confirm the current Orange Book listing and any remaining enforceable claims for a specific market date. The commercial formulation itself is conventional, and no publicly established extended-release or device-based barrier is associated with the labeled Letairis tablet.[1,3]

For a generic entrant, the relevant patent questions are:

1. Which U.S. patents are listed in the Orange Book for the reference product?
2. Are the listed claims directed to composition, treatment method, or formulation?
3. Which patents remain unexpired after pediatric extensions, terminal disclaimers, or adjustments?
4. Does the ANDA require a Paragraph IV certification?
5. Are any settlement agreements restricting launch timing or manufacturing sources?
6. Do foreign jurisdictions retain protection after U.S. expiration?

What is the Orange Book status of Letairis?

Letairis is an FDA-approved small-molecule reference product. Its generic pathway is the ANDA route, and ambrisentan generics have entered the U.S. market.[3,4]

Orange Book analysis should distinguish:

• Listed patents that have expired.
• Patents that remain listed but do not block an ANDA approval date.
• Method-of-use patents that may be addressed through a section viii statement.
• Patent certifications made by individual ANDA applicants.
• Regulatory exclusivity, which is separate from patent term.

Patent status is applicant-specific. A Paragraph IV certification by one generic company does not establish that every generic applicant has identical litigation exposure.

When did Letairis lose exclusivity and when can generics launch?

Letairis has lost the practical exclusivity associated with a single-source branded product. FDA-approved generic ambrisentan products are commercially available, and the market is now exposed to price competition.[4]

Exclusivity or access factor	Commercial effect
New drug exclusivity	No longer the primary market barrier
Patent exclusivity	Must be assessed patent by patent and jurisdiction by jurisdiction
Generic approval	Available through ANDA pathway
REMS or restricted distribution	May affect dispensing and compliance operations
Pediatric exclusivity	Could alter a specific patent or regulatory date
Formulation complexity	Low relative to modified-release or injectable products
Biosimilar substitution	Not relevant because ambrisentan is a small molecule

A generic launch scenario depends on the applicant’s patent certification, litigation outcome, settlement terms, FDA approval timing, manufacturing readiness, and commercial decision to launch. Approved products may launch immediately after relevant barriers fall, at an agreed settlement date, or on an at-risk basis where legally permitted.

Which companies are challenging Letairis?

Ambrisentan generic competition has developed through ANDA applicants and commercial generic manufacturers. The competitive field can include companies that:

• Submit Paragraph IV certifications.
• Receive tentative or final FDA approval.
• Launch through their own supply chains.
• License or acquire an approved ANDA.
• Use contract development and manufacturing organizations.
• Supply hospital, specialty-pharmacy, or distributor channels.

Company-level litigation and settlement positions can change by applicant. The operative diligence source is the FDA Orange Book, FDA approval letters, Abbreviated New Drug Application records where available, and federal court dockets.[3,5]

A buyer or licensor should not treat an approved ANDA as proof of immediate unrestricted launch. Patent certifications, court orders, settlement agreements, supply agreements, and product-specific labeling obligations can affect the effective entry date.

What commercial opportunities exist for Letairis excipients?

Lactose-free ambrisentan

A lactose-free formulation is the clearest excipient-led opportunity. It can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent, subject to compatibility, dissolution, compressibility, and regulatory acceptability.

The commercial value is likely niche rather than mass-market. PAH is a specialty indication, and prescribing decisions are driven primarily by clinical suitability, payer access, supply, and price. Lactose exclusion can still improve formulary acceptance and create a differentiated product for specialty distribution.

Low-cost high-throughput manufacturing

The larger opportunity is manufacturing economics. A formulation that supports direct compression, short blending cycles, low coating weight, and high tablet yield can improve gross margin in a price-eroding generic market.

Important process targets include:

• High blend uniformity at 5 mg.
• Low tablet-weight variability.
• Controlled friability.
• Fast disintegration.
• Consistent dissolution.
• Low punch sticking.
• Stable film-coating color.
• Minimal changeover time between strengths.

Excipient supply and dual sourcing

Excipient suppliers can target manufacturers with:

• Direct-compression microcrystalline cellulose.
• Consistent pharmaceutical-grade croscarmellose sodium.
• Low-peroxide or low-moisture grades where justified.
• Non-lactose diluent systems.
• Ready-to-use film coatings.
• Color systems adapted to regional regulations.
• Magnesium stearate alternatives for improved process control.

Dual sourcing is commercially relevant because ambrisentan is a chronic-use product. Shortages or quality holds can shift pharmacy and specialty-distributor purchasing rapidly.

Lifecycle products

Potential lifecycle products include:

• Smaller tablets for swallowing difficulty.
• Color-free tablets.
• Lactose-free tablets.
• Alternative packaging with improved moisture protection.
• Fixed-dose combinations with other PAH medicines, subject to clinical and regulatory requirements.
• Pediatric dosage forms if an approved indication and market need exist.
• Tablets optimized for lower-cost global markets.

A powder-for-reconstitution or oral-liquid product would face greater stability, taste, preservative, packaging, and dosing-device requirements. It is a higher-cost opportunity than a conventional tablet but may offer more differentiation.

How strong is the patent estate for Letairis?

The patent estate is stronger as a historical small-molecule product estate than as a current excipient barrier. The labeled tablet does not rely on an unusually complex formulation technology. That reduces the risk that a conventional generic will infringe a difficult-to-design-around formulation claim.

Patent strength should be assessed across four categories:

Patent category	Relevance to generic risk
Ambrisentan composition claims	Potentially high if unexpired and enforceable
Pharmaceutical composition claims	Moderate to high depending on claim scope
Method-of-use claims	Potentially addressable through labeling or section viii strategy
Manufacturing claims	Relevant if the generic process falls within claim scope
Excipient-specific claims	Low apparent importance for the conventional tablet

The principal freedom-to-operate risk is usually the active ingredient and use-patent estate, not the basic use of lactose, microcrystalline cellulose, croscarmellose sodium, or magnesium stearate.

What patent litigation affects ambrisentan generic entry?

Relevant disputes can arise from:

• Paragraph IV certifications.
• ANDA filing dates.
• Hatch-Waxman patent-infringement complaints.
• Thirty-month stays.
• Preliminary injunction requests.
• Settlement agreements.
• Authorized-generic arrangements.
• At-risk launch decisions.

Litigation must be reviewed at the applicant level. A settlement involving one ANDA sponsor may not apply to another sponsor unless the agreement or court order provides otherwise. Generic manufacturers should also examine whether a settlement includes launch restrictions, supply limitations, geographic exclusions, or non-compete provisions.

Are biosimilars a risk to Letairis?

No. Biosimilars compete with biologic products. Ambrisentan is a chemically synthesized small molecule, so competitive entry occurs through generic-drug regulation rather than the biosimilar pathway.[2]

The relevant competitive risks are:

• Additional ANDA approvals.
• Authorized-generic supply.
• Price erosion.
• Specialty-pharmacy substitution.
• Distributor consolidation.
• PAH treatment substitution with other endothelin receptor antagonists.
• Combination therapy competition.

How does Letairis compare with competing PAH drugs?

Letairis competes primarily with other PAH therapies, not only with generic ambrisentan.

Product or class	Active ingredient	Formulation profile	Competitive position
Letairis	Ambrisentan	Immediate-release tablet	Reference product, now exposed to generic competition
Generic ambrisentan	Ambrisentan	Immediate-release tablet	Price-led competition
Tracleer and generics	Bosentan	Immediate-release tablet and other forms	Broader interaction and monitoring considerations
Opsumit	Macitentan	Immediate-release tablet	Branded endothelin receptor antagonist competitor
Uptravi	Selexipag	Oral tablet	Different pharmacology and market positioning
PDE-5 inhibitors	Sildenafil, tadalafil	Oral tablets	Alternative PAH treatment class
Prostacyclin therapies	Various	Injectable, inhaled, or oral	More complex delivery and treatment burden

Ambrisentan’s excipient opportunity is therefore tied to maintaining reliable, low-cost oral therapy while addressing formulary and patient-use preferences.

What FDA regulatory issues affect an excipient-led generic?

The key FDA issues are pharmaceutical equivalence, bioequivalence, impurity control, manufacturing consistency, labeling, and inactive-ingredient suitability.[2,6]

A changed excipient system can trigger development work in:

• Comparative dissolution.
• Stability under ICH conditions.
• Extractables and leachables for packaging.
• Nitrosamine and elemental-impurity risk assessments where applicable.
• Residual solvent control.
• Color additive compliance.
• Excipient qualification and supplier change control.
• Inactive-ingredient precedent and maximum daily exposure review.

A conventional excipient substitution is commercially attractive only if it does not create a disproportionate regulatory burden. The formulation should be optimized for reliable approval and scale-up, not novelty alone.

What geographic opportunities exist for ambrisentan excipients and generics?

The U.S. market is governed by the FDA ANDA and Orange Book system. Europe, Japan, Canada, Australia, and emerging markets apply different rules for generic equivalence, patent linkage, excipient labeling, and colorant use.

Geographic opportunities include:

• Lactose-free products in markets with strong excipient disclosure expectations.
• Dye-free products where certain colorants face regulatory or consumer pressure.
• Common formulations for multiple jurisdictions.
• Local production in markets with procurement preferences.
• Regional film-coating systems aligned with permitted colorants.
• Dual-source excipient supply for chronic PAH products.

Patent term, regulatory data protection, product registration, and local manufacturing requirements must be reviewed separately in each jurisdiction. U.S. generic approval does not establish freedom to launch in Europe or other markets.

Key Takeaways

• Letairis is a 5 mg and 10 mg immediate-release ambrisentan tablet.
• Its inactive ingredients are conventional and include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a polyvinyl alcohol-based film coating.[1]
• The strongest excipient-led opportunity is a lactose-free or otherwise differentiated generic formulation.
• The largest economic opportunity is manufacturing efficiency, especially blend uniformity and high-yield production at the 5 mg strength.
• Ambrisentan is a small molecule, so biosimilars are not relevant.
• Generic entry is governed by ANDA approval, patent certifications, litigation, settlements, and applicant-specific launch rights.
• The commercial patent barrier is more likely to involve active-ingredient, use, or composition claims than the conventional excipient system.
• Geographic opportunities depend on local patent status, excipient rules, colorant requirements, and generic-substitution policies.
• A formulation platform supporting both strengths can reduce development, validation, and inventory costs.

FAQs

Can ambrisentan tablets be manufactured without lactose?

Yes. A lactose-free formulation can use an alternative diluent, provided it meets dissolution, content-uniformity, stability, compression, and regulatory requirements.

Is a new excipient required to obtain an ambrisentan generic?

No. A generic manufacturer can use established pharmaceutical excipients. Novel excipients may increase regulatory and development complexity without creating proportional commercial value.

Does Letairis require a complex drug-delivery system?

No. The labeled product is a conventional immediate-release film-coated tablet. Its main technical risks are low-dose uniformity, dissolution, coating consistency, and scale-up.

Can a generic ambrisentan company market a dye-free tablet?

Potentially, subject to formulation performance, inactive-ingredient review, labeling, product appearance requirements, and approval by the relevant regulator.

Is a fixed-dose ambrisentan combination a realistic lifecycle opportunity?

It is technically possible but commercially and clinically more demanding than a conventional generic. The product would require a justified combination indication, compatible pharmacokinetics, stability data, clinical or regulatory support, and a defensible market-access strategy.

References

1. U.S. Food and Drug Administration. (2023). Letairis (ambrisentan) prescribing information.
2. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format of abbreviated new drug applications.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. U.S. Courts. (2024). Public access to court electronic records, PACER.
6. U.S. Food and Drug Administration. (2016). Inactive ingredient database.